Resource Constraints Preventing FDA From Getting Full Benefits of QbR
This article was originally published in The Gold Sheet
Executive Summary
Generic drug reviews falling behind despite new question-based-review approach due to increasing workload and declining resources, including a lack of user fees. How to improve QbR and microbiology submissions and reduce first-cycle review times. How more frequently updated dissolution and inactive ingredient databases could help.